19TH EDITION

Remington: Practice of

ALFONSO R GENNARO
Chairman of the Editorial Board and Editor

The Science and Pharmacy

1995

MACK PUBLISHING COMPANY
Easton, Pennsylvania 18042

Library of Congress Catalog Card No. 60-53334

ISBN 0-912734-04-3

The use of structural formulas from USAN and the USP Dictionary of Drug Names is by permission of The USP Convention. The Convention is not responsible for any inaccuracy contained herein.

NOTICE—This text is not intended to represent, nor shall it be interpreted to be, the equivalent of or a substitute for the official United States Pharmacopeia (USP) and/or the National Formulary (NF). In the event of any difference or discrepancy between the current official USP or NF standards of strength, quality, purity, packaging and labeling for drugs and representations of them herein, the context and effect of the official compendia shall prevail.

Printed in the United States of America by the Mack Printing Company, Easton, Pennsylvania

Table 1—Rates of Entry of Drugs in CSF and the Degrees of Ionization of Drugs at pH 7.4[7]

Drug/chemical	% binding to plasma protein	pK_a[a]	% un-ionized at pH 7.4	Permeability constant ($P\ min^{-1}$) ± S.E.
Drugs mainly ionized at pH 7.4				
6-Sulfosalicylic acid	22	(strong)	0	<0.0001
N-Methylnicotinamide	<10	(strong)	0	0.0005 ± 0.00006
6-Nitrosalicylic acid	42	3.3	0.001	0.001 ± 0.0001
Salicylic acid	40	3.0	0.004	0.003 ± 0.0004
Mecamylamine	20	11.2	0.016	0.021 ± 0.0016
Quinine	76	8.4	0.09	0.078 ± 0.0061
Drugs mainly un-ionized at pH 7.4				
Barbital	<2	7.5	55.7	0.026 ± 0.0023
Thiopental	76	7.6	61.3	0.30 ± 0.051
Pentobarbital	40	8.1	88.4	0.17 ± 0.014
Aminopyrine	20	5.0	99.6	0.25 ± 0.020
Aniline	15	4.6	99.8	0.40 ± 0.042
Sulfaguanidine	6	>10.0[b]	>99.8	0.003 ± 0.0003
Antipyrine	8	1.4	>99.9	0.12 ± 0.013
N-Acetyl-4-aminoantipyrine	<3	0.5	>99.9	0.012 ± 0.0010

[a] The dissociation constant of both acids and bases is expressed as the pK_a; the negative logarithm of the acidic dissociation constant.
[b] Sulfaguanidine has a very weakly acidic group (pK_a > 10) and two very weakly basic groups (pK_a 2.75 and 0.5). Consequently, the compound is almost completely undissociated at pH 7.4.

for all practical purposes, only the un-ionized form is said to pass through the membrane. This has become known as the *principle of nonionic diffusion*.

This principle is the reason that only the concentrations of the un-ionized form of the barbiturates are plotted in Fig 9.

For the purpose of further illustrating the principle, Table 1 is provided.[7] In the table, the permeability constants for penetration into the cerebral spinal fluid of rats are higher for un-ionized drugs than for ionized ones. The apparent exceptions—barbital, sulfaguanidine and acetylaminoantipyrine—may be explained by the dipolarity of the un-ionized molecules. With barbital, the two lipophilic ethyl groups are too small to compensate for the considerable dipolarity of the un-ionized barbituric acid ring; also it may be seen that barbital is appreciably ionized, which contributes to the relatively small permeability constant. Sulfaguanidine and acetylaminoantipyrine are both very polar molecules. Mecamylamine also might be considered an exception, since it shows a modest permeability even though strongly ionized; there is no dipolarity in mecamylamine except in the amino group.

Absorption of Drugs

Absorption is the process of movement of a drug from the site of application into the extracellular compartment of the body. Inasmuch as there is a great similarity among the various membranes that a drug may pass through in order to gain access to the extracellular fluid, it might be expected that the particular site of application (or *route*) would make little difference to the successful absorption of the drug. In actual fact, it makes a great deal of difference; many factors, other than the structure and composition of the membrane, determine the ease with which a drug is absorbed. These factors are discussed in the following sections, along with an account of the ways that drug formulations may be manipulated to alter the ability of a drug to be absorbed readily.

Routes of Administration

Drugs may be administered by many different routes. The various routes include oral, rectal, sublingual or buccal, parenteral, inhalation and topical. The choice of a route depends upon both convenience and necessity.

Oral Route—This is obviously the most convenient route for access to the systemic circulation, providing that various factors do not militate against this route. Oral administration does not always give rise to sufficiently high plasma concentrations to be effective; some drugs are absorbed unpredictably or erratically; patients occasionally have an absorption malfunction. Drugs may not be given by mouth to patients with gastrointestinal intolerance, or who are in preparation for anesthesia or who have had gastrointestinal surgery. Oral administration also is precluded in coma.

Rectal Route—Drugs that ordinarily are administered by the oral route usually can be administered by injection or by the alternative *lower enteral* route, through the anal portal into the rectum or lower intestine. With regard to the latter, *rectal suppositories* or *retention enemas* formerly were used quite frequently, but their popularity has abated somewhat, owing to improvements in parenteral preparations. Nevertheless, they continue to be valid and, sometimes, very important ways of administering a drug, especially in pediatrics and geriatrics. In Fig 10[8] the availability of a drug by retention enema may be compared with that by the intravenous and oral route and rectal suppository administration. It is apparent that the retention enema may be a very satisfactory means of administration but that rectal suppositories may be inadequate where rapid absorption and high plasma levels are required. The illustration is not intended to lead the reader to the conclusion that a retention enema always will give more prompt and higher blood levels than the oral route, for converse findings for the same drug have been reported,[9] but, rather, to show that the retention enema may offer a useful substitute for the oral route.

Sublingual or Buccal Route—Even though an adequate plasma concentration eventually may be achievable by the oral route, it may rise much too slowly for use in some situations where a rapid response is desired. In such situations parenteral therapy usually is indicated. However, the patients with angina pectoris may get quite prompt relief from an acute attack by the *sublingual* or *buccal* administration of nitroglycerin, so that parenteral administration may be avoided. When only small amounts of drugs are required to gain access to the blood, the buccal route may be very satisfactory, providing the physicochemical prerequisites for absorption by this route are present in the drug and dosage form. Only a few drugs may be given successfully by this route.

Parenteral Routes—These routes, by definition, include any route other than the oral-gastrointestinal (enteral) tract,

We gratefully acknowledge the co-operation of the surgical and gynaecological services of Stobhill General Hospital and Southern General Hospital, Glasgow.

PETER J.W. SCOTT
Department of Geriatric Medicine, Stobhill General Hospital, Glasgow G21 3UW

JOHN L. REID
Department of Materia Medica, University of Glasgow, Stobhill General Hospital, Glasgow G21 3UW

Received July 10, 1981

References

ADNAMS, I.B. & SCARPACE, P.J. (1981). Human lymphocyte beta-adrenergic receptors are unaltered with age. *J. Gerontol.*, 36, 298–301.

BERTEL, O., BÜHLER, F.R., KIOWSKI, W. & LÖTOLD, B.E. (1980). Decreased beta-adrenoreceptor responsiveness as related to age, blood pressure and plasma catecholamines in patients with essential hypertension. *Hypertension*, 2, 130–138.

CARRIER, G.O., JACKSON, C.V. & OWEN, M.P. (1979). Influence of age on norepinephrine-induced vascular contractions as a function of extracellular calcium. *Res. Comm. Chem. Path. Pharmac.*, 26, 433–446.

ELLIOT, H.L., RUBIN, P.C., SCOTT, P.J.W. & REID, J.L. (1981). Vascular alpha receptors and age. Studies with prazosin and phenylephrine. *Eur. J. clin. Invest.*, 11, 9.

FLEISCH, J.H. (1980). Age related changes in the sensitivity of blood vessels to drugs. *Pharmac. Ther.*, 9, 477–487.

GRAY, S.D. (1977). Reactivity of neonatal canine aortic strips. *Biol. Neonate*, 31, 10–14.

HAYASHI, S. & TUDA, N. (1978). Age related changes in the response of rabbit isolated aortae to vasoactive agents. *Br. J. Pharmac.*, 64, 229–237.

KIOWSKI, W., BÜHLER, F.R., VAN BRUMMELEN, P. & AMANN, F.W. (1981). Plasma noradrenaline concentration and alpha-adrenoceptor mediated vasoconstriction in normotensive and hypertensive man. *Clin. Sci.*, 60, 485–489.

SCHOCKEN, D.D. & ROTH, G.S. (1977). Reduced beta-adrenergic receptor concentrations in ageing man. *Nature*, 267, 856–858.

VESTAL, R.E., WOOD, A.J.J. & SHAND, D.G. (1979). Reduced beta-adrenoceptor sensitivity in the elderly. *Clin. Pharmac. Ther.*, 26, 181–186.

YIN, F.C., SPURGEON, H.A., RAIZES, G.S., GREEN, H.L., WEISFELDT, M.L. & SHOCK, N.W. (1976). Age associated decrease in chronotropic response to isoproterenol. *Circulation*, 54, Suppl. II, 167.

10^{-3}

rtical bars represent s.d. Δ 30–49 mean 73 years, n = 8).

lewed the literature concerning n the sensitivity of animal aortae e evidence is conflicting. Currie trated a decrease in sensitivity n the rat. Gray (1977) found an ty with age in the dog, while 78) found no change with age in these studies involved immature n as opposed to a comparison d senescent. The present study l elderly subjects. There was no n the sensitivity of human arterial aline. This is found when the se is considered alone or when it non-receptor mediated contrac ssium.

ries for these experiments had to cents with an underlying disease. no surgery, receiving medication adrenergic nervous system nor underlying arterial disease. Cur ed by recent studies *in vivo* with eers (Elliot *et al.*, 1981) and with in young and old subjects).

an find no evidence *in vivo* that vascular α-adrenoceptor decreasing age. Further studies will ermine whether changes in β- n subtypes of α-adrenoceptors ardiovascular system.

BIOAVAILABILITY OF SUBLINGUAL ERGOTAMINE

Sublingual ergotamine has been used for years in the treatment of migraine attacks without any proof of its effectiveness. In a double-blind clinical trial no difference in relief was found between sublingual ergotamine and placebo (Crobks *et al.*, 1964). Similarly, a study on the buccal absorption of ergotamine indicated that it is unlikely for therapeutically useful amounts of drug to be absorbed across the buccal membrane (Sutherland *et al.*, 1974).

In contrast, Winsor (1981) in a nonblind cross-over study with finger-plethysmography found that the peripheral vasoconstrictory effect of ergotamine was equal after 0.25 mg intramuscularly or 2 mg sublingually, and significantly different from sublingual placebo. The two forms at those doses should thus be equally effective in migraine. With a high performance liquid chromatographic (h.p.l.c.) assay for ergotamine, with a detection level of 0.1 ng/ml in plasma (Edlund, 1981), we have investigated several administration forms of the drug. The results for sublingual ergotamine are reported as they cast serious doubt on the equipotency of sublingual and intramuscular forms of ergotamine.

Four volunteers (medical personnel, non-migraineurs) kept a sublingual tablet of 2 mg ergotamine tartrate (Lingraine®, Winthrop) under the tongue until dissolved. Blood was drawn after 5, 10, 20, 30, 60, 90 and 120 min. The samples were immediately centrifuged and kept deep frozen until analysed by the h.p.l.c. method. Ergotamine above the detection level was not found in any of the samples. Then the procedure was repeated in the same volunteers with another batch of Lingraine®. Again no ergotamine could be detected. The manufacturer informed us that both batches of Lingraine® were more than 2 years before their expiry date. For comparison we selected 4 migraine patients, who during the same period had their plasma levels of ergotamine determined with h.p.l.c. after 0.5 mg ergotamine tartrate/70 kg body weight intramuscularly. The mean and range of ergotamine levels in ng/ml plasma were after 30 min: 0.96 (0.48–1.41), after 60 min: 0.80 (0.57–1.07) and after 120 min: 0.57 (0.43–0.71). Even corrected to a dose of 0.25 mg the plasma levels of ergotamine are clearly above the detection level of 0.1 ng/ml.

These results were not obtained in a regular cross-over study. However, the discrepancy in plasma

Br. J. clin. Pharmac. (1982), 13

levels between sublingual and intramuscular ergotamine is so striking that it is unlikely for ergotamine 2 mg sublingually to have the same bioavailability as 0.25 mg intramuscularly.

Are the two forms of ergotamine then equipotent in their vasoconstrictory effect due to same active metabolites not measured by the specific h.p.l.c. method? Before going into speculations along these lines, we would suggest that the results with finger-plethysmography should be confirmed in a placebo controlled double-blind study with direct measurements of the vasoconstrictory effect of ergotamine. Our main objection against the results with finger-plethysmography is that the effect of the reference form, intramuscular ergotamine, only had a duration of 90 min on venous occlusion blood flow. This short duration of action is not in agreement with recent investigations on arteries with ergotamine (Tfelt-Hansen *et al.*, 1980) and on veins with dihydroergotamine (Aellig, 1981). The duration of these ergot alkaloids vasoconstrictory effect in man was found to be at least 24 and 8 h respectively. Further, a dose-response curve for the biological effect should be established before the question of biological equipotency can be answered satisfactorily.

If proven to be equipotent to parenteral ergotamine in such studies, sublingual ergotamine should undergo a controlled clinical trial in migraine.

P. TFELT-HANSEN
Department of Neurology, Rigshospitalet, Copenhagen, DK-2100, Denmark

L. PAALZOW & J.J. IBRAHEEM
Department of Biopharmaceutics, University of Uppsala, Biomedical Center, Uppsala, Sweden

Received July 27, 1981

References

AELLIG, W. H. (1981). A new technique for recording compliance of human hand veins. *Br. J. clin. Pharmac.*, 11, 237–243.

CROOKS, J., STEPHEN, S.A. & BRASS, W. (1964). Clinical trial of inhaled ergotamine tartrate. *Br. med. J.*, 1, 221–224.

EDLUND, P.O. (1981). Determination of ergot alkaloids in plasma by liquid chromatography and fluorescence detection. *J. Chromatogr.*, (in press).

SUTHERLAND, J.M., HOOPER, W.D., EADIE, M.J. & THYRER, J.H. (1974). Buccal absorption of ergotamine. *J. Neurol. Neurosurg. Psychiat.*, 37, 1116–1120.

TFELT-HANSEN, P., EICKHOFF, J.H. & OLESEN, J. (1981). The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: Methodological aspects and time effect curve. *Acta Pharmacol. Tox.*, 47, 151–156.

WINSOR, T. (1981). Plethysmographic comparison of sublingual and intramuscular ergotamine. *Clin. Pharmacol. Ther.*, 29, 94–99.

VERAPAMIL BIOAVAILABILITY AND DOSAGE IN LIVER DISEASE

May we be permitted to comment on the critical remarks made by Somogyi *et al.* (1981) on our dosage recommendations for verapamil and at the same time discuss the wider significance of verapamil dosage in liver disease.

Somogyi *et al.* (1981) recommend that the oral dose of verapamil in liver cirrhosis patients should be greatly reduced, and more so than required in the case of the intravenous dose. The oral dose they recommend is as little as one fifth of that used in patients with normal liver function. In our dosage recommendations, based on intravenous administration in patients with cirrhosis, hepatitis and fatty liver disease, a reduction to about one third was indicated, although there was considerable inter-patient variation (Woodcock *et al.*, 1979). Verapamil clearance data following oral treatment in liver patients were not available at this time. Somogyi *et al.* (1981) state that we 'failed to appreciate the difference between oral and intravenous clearance of verapamil' and thus imply that we were erroneous in the interpretation of our observations. This statement, apart from being incorrect (the first pass effect of verapamil is common knowledge since the report of Shomers *et al.* (1976)), misses the fundamental point which is that the large reduction, to one fifth, in the oral dose of verapamil recommended by themselves, applies only to liver cirrhosis patients who have marked intra- and extrahepatic shunts. This fact was omitted from their discussion.

We have reported observations on liver cirrhosis patients in whom the bioavailability of verapamil was the same as in healthy subjects despite a greatly reduced systemic clearance (Woodcock *et al.*, 1981). In patients with fatty liver the first pass extraction was increased and the bioavailability actually lower than normal. A higher than normal extraction of verapamil is, according to Wilkinson & Shand (1975), to be expected when the rate of blood flow through the liver is reduced. In these patients there was thus no evidence for the development of hepatic shunts and a dosage reduction of the magnitude suggested by

Br. J. clin. Pharmac. (1

Somogyi *et al.* (1981)
patients studied by So
and were undergoin
because of excessive
therefore a selected g
verapamil bioavailabi
normal and thus the
is a pathological char
to use the verapam
patients to make goo
all liver patients in cli

Liver disease pati
verapamil clearance
increased, unchanged
suitable dosage reg
necessary to consider
patient. Our present
done to achieve an
however, and a th
plasma concentration

We now know, th
that the intrinsic cle
bility in liver dis
(Woodcock *et al.*, 1

References

BJÖRKMAN, M., EI
EICHELBAUM, M.
verapamil in man.
SOMOGYI, A., ALBR
& EICHELBAUM,
availability and E
with liver cirrhosis
WILKINSON, G.R. &
approach to hepa
Ther., 18, 377–39
WOODCOCK, B.G., P
Verapamil and
during long-term
obstructive cardi
3, 17–23.
WOODCOCK, B.G

DOSE-DEPEN
SLOW RELEA
DISEASE

Slow release theo
administered to p
the control of
1980). The elimin
is influenced by
commonly preser
days obstruction
disease, smoking
Powell *et al.*, 197
dependent pharm